AU Patent

AU2017310529B2 — Protein kinase regulators

Assigned to Madera Therapeutics LLC · Expires 2021-08-19 · 5y expired

What this patent protects

The present invention provides, in part, novel compounds and pharmaceutically acceptable salts capable of modulating the activity of kinases, including Akt, ERK and MEK. Such modulation affects biological functions, for example, by inhibiting cell proliferation and/or inducing ap…

USPTO Abstract

The present invention provides, in part, novel compounds and pharmaceutically acceptable salts capable of modulating the activity of kinases, including Akt, ERK and MEK. Such modulation affects biological functions, for example, by inhibiting cell proliferation and/or inducing apoptosis. Also provided are pharmaceutical compositions and medicaments, comprising the compounds or salts of the invention, alone or in combination with other therapeutic agents or palliative agents.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017310529B2
Jurisdiction
AU
Classification
—
Expires
2021-08-19
Drug substance claim
No
Drug product claim
No
Assignee
Madera Therapeutics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.